Rate My Professor Kevin Ly

Dr. Ly's current research centers on the role of p53 isoforms, particularly a Δ133p53-like isoform, in modulating anti-tumour immunotherapy responses. His investigations examine p53 isoforms in the contexts of cancer, inflammatory bowel disease, and obesity, with the goal of establishing Δ133p53 as a predictive biomarker for patient responses to immunotherapy and enhancing immune-targeted therapies for solid tumors such as colorectal cancer. This work is funded by a Cancer Society of New Zealand Postdoctoral Fellowship. Recent publications reflect his shift toward immunology and cancer therapy, including 'Immune checkpoint inhibitor therapy for metastatic melanoma: What should we focus on to improve the clinical outcomes?' co-authored with S.M. Hossain, A. Braithwaite, and K. Li (International Journal of Molecular Sciences, 25(18), 10120, 2024) and 'Importance of crosstalk between the microbiota and the neuroimmune system for tissue homeostasis' with K. Li, S. Mehta, and A. Braithwaite (Clinical & Translational Immunology, 11, e1394, 2022). Additional contributions include studies on human papillomavirus (HPV) impacts on immune cells, such as 'Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response' (Scientific Reports, 8, 2373, 2018). Dr. Ly is affiliated with the Maurice Wilkins Centre New Zealand and is a member of the Australia and New Zealand Society for Immunology.